Apogepha

Apogepha is a century-old, private German pharmaceutical company with a deep specialization in urology. It has a commercial-stage portfolio spanning small molecule drugs, medical devices like BCG for bladder cancer, and consumer-facing nutraceuticals for conditions such as benign prostatic hyperplasia (BPH) and cystitis. The company leverages its heritage and focus on urology to maintain a strong presence in the German-speaking market, supported by continuous product introductions and active engagement with the medical community through scientific events.

Focused urology development and commercialization platform with expertise in small molecules, phytopharmaceuticals, and biological agents (BCG) for urological conditions.

Apogepha competes in the urology space against large multinational pharmaceutical companies (e.g., Astellas, Pfizer, Bayer) and generic manufacturers. Its differentiation lies in its pure-play urology focus, deep relationships with specialists, and a mixed portfolio of pharmaceuticals and consumer products. In the BCG segment, it competes with other suppliers like Merck and Sanofi.